Postherpetic Neuralgia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 98 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Postherpetic Neuralgia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H2 2014', provides an overview of the Postherpetic Neuralgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Postherpetic Neuralgia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Postherpetic Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Postherpetic Neuralgia Overview 8
Therapeutics Development 9
Pipeline Products for Postherpetic Neuralgia - Overview 9
Pipeline Products for Postherpetic Neuralgia - Comparative Analysis 10
Postherpetic Neuralgia - Therapeutics under Development by Companies 11
Postherpetic Neuralgia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Postherpetic Neuralgia - Products under Development by Companies 17
Postherpetic Neuralgia - Companies Involved in Therapeutics Development 18
Bristol-Myers Squibb Company 18
Allergan, Inc. 19
Acorda Therapeutics, Inc. 20
Astellas Pharma Inc. 21
Daewoong Pharmaceutical Co., Ltd. 22
Pfizer Inc. 23
Purdue Pharma L.P. 24
Teva Pharmaceutical Industries Limited 25
Impax Laboratories, Inc. 26
Nuvo Research Inc. 27
Arcion Therapeutics, Inc. 28
NeurAxon, Inc. 29
Winston Pharmaceuticals, Inc. 30
Spinifex Pharmaceuticals Pty Limited 31
Relmada Therapeutics, Inc. 32
Aestus Therapeutics, Inc. 33
Convergence Pharmaceuticals Ltd. 34
Immune Pharmaceuticals, Inc. 35
Scilex Pharmaceuticals, Inc. 36
Postherpetic Neuralgia - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(amitriptyline + ketamine) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pregabalin CR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bupivacaine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NP-1998 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NXN-462 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TV-45070 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
zucapsaicin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
senrebotase - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
DWP-05195 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
EMA-401 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BMS-954561 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Atx08-001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CNV-2197944 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ASP-8477 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
V-116517 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Flexicaine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
lidocaine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
lidocaine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
mepivacaine hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
(naltrexone + clonidine) - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PRTT-200 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Postherpetic Neuralgia - Recent Pipeline Updates 77
Postherpetic Neuralgia - Dormant Projects 87
Postherpetic Neuralgia - Discontinued Products 88
Postherpetic Neuralgia - Product Development Milestones 89
Featured News & Press Releases 89
Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China 89
Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 89
Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 90
May 19, 2014: Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido 90
Mar 24, 2014: Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido 91
Feb 21, 2014: Endo Announces Resolution of Government Investigation 91
Feb 21, 2014: Endo Pharmaceuticals and Endo Health Solutions to Pay $192.7 Million to Resolve Criminal and Civil Liability Relating to Marketing of Prescription Drug Lidoderm for Unapproved Uses 92
Feb 05, 2014: Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia 94
Jul 08, 2013: Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 95
Jun 28, 2013: Two New Formulations of E Keppra Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables
Number of Products under Development for Postherpetic Neuralgia, H2 2014 9
Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Development by Companies, H2 2014 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Postherpetic Neuralgia - Pipeline by Bristol-Myers Squibb Company, H2 2014 18
Postherpetic Neuralgia - Pipeline by Allergan, Inc., H2 2014 19
Postherpetic Neuralgia - Pipeline by Acorda Therapeutics, Inc., H2 2014 20
Postherpetic Neuralgia - Pipeline by Astellas Pharma Inc., H2 2014 21
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 22
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2014 23
Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H2 2014 24
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 25
Postherpetic Neuralgia - Pipeline by Impax Laboratories, Inc., H2 2014 26
Postherpetic Neuralgia - Pipeline by Nuvo Research Inc., H2 2014 27
Postherpetic Neuralgia - Pipeline by Arcion Therapeutics, Inc., H2 2014 28
Postherpetic Neuralgia - Pipeline by NeurAxon, Inc., H2 2014 29
Postherpetic Neuralgia - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 30
Postherpetic Neuralgia - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2014 31
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2014 32
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2014 33
Postherpetic Neuralgia - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 34
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 35
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H2 2014 77
Postherpetic Neuralgia - Dormant Projects, H2 2014 87
Postherpetic Neuralgia - Discontinued Products, H2 2014 88